https://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rssBioCentury feeden-USCopyright 2026 BioCentury, Inc.RSS Generatorhttps://us-west-2-biocentury.graphassets.com/AqjgGpburRt67lm6SEY2Oz/z8oGLhcsSyi6zlYTKFwihttps://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rsshttps://www.biocentury.com/article/660396/similar-regulatory-clocks-divergent-paths-to-study-starthttps://www.biocentury.com/article/660396/similar-regulatory-clocks-divergent-paths-to-study-start?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTSIMILAR REGULATORY CLOCKS, DIVERGENT PATHS TO STUDY STARTReview structure, dedicated trial units, and site operations together determine how quickly clinical trials reach first patientFri, 21 Aug 2026 14:56:23 -0700https://www.biocentury.com/article/660592/buoyed-by-readout-amylyx-banks-500m-ahead-of-submission-finance-reporthttps://www.biocentury.com/article/660592/buoyed-by-readout-amylyx-banks-500m-ahead-of-submission-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEBUOYED BY READOUT, AMYLYX BANKS $500M AHEAD OF SUBMISSION: FINANCE REPORTPlus: Ambros lines up $150M PIPE as it heads to NASDAQ via reverse merger; and moreFri, 21 Aug 2026 13:51:30 -0700https://www.biocentury.com/article/660470/loosening-the-reins-the-bold-risks-required-to-overhaul-first-in-human-trialshttps://www.biocentury.com/article/660470/loosening-the-reins-the-bold-risks-required-to-overhaul-first-in-human-trials?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONLOOSENING THE REINS: THE BOLD RISKS REQUIRED TO OVERHAUL FIRST-IN-HUMAN TRIALS Back to School 2026: China has brought new urgency to a longstanding bottleneck. Transformational reform will require rethinking the risk-control paradigmFri, 21 Aug 2026 13:10:44 -0700https://www.biocentury.com/article/660586/ai-exec-reis-filho-leaves-astrazeneca-for-strategy-role-at-foresite-labshttps://www.biocentury.com/article/660586/ai-exec-reis-filho-leaves-astrazeneca-for-strategy-role-at-foresite-labs?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSAI EXEC REIS-FILHO LEAVES ASTRAZENECA FOR STRATEGY ROLE AT FORESITE LABSPlus: New CEOs at Neumora and Juvena; and moreThu, 20 Aug 2026 16:58:33 -0700https://www.biocentury.com/article/660583/mapping-first-steps-toward-scaling-genetic-medicines-c-path-s-romero-on-the-biocentury-showhttps://www.biocentury.com/article/660583/mapping-first-steps-toward-scaling-genetic-medicines-c-path-s-romero-on-the-biocentury-show?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONMAPPING FIRST STEPS TOWARD SCALING GENETIC MEDICINES: C-PATH’S ROMERO ON THE BIOCENTURY SHOWOne to Millions will begin with shared ASO safety data,Thu, 20 Aug 2026 16:54:38 -0700https://www.biocentury.com/article/660387/denmark-spain-and-the-u-k-build-fast-lanes-for-fih-trials-back-to-school-2026https://www.biocentury.com/article/660387/denmark-spain-and-the-u-k-build-fast-lanes-for-fih-trials-back-to-school-2026?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONDENMARK, SPAIN, AND THE U.K. BUILD FAST LANES FOR FIH TRIALS — BACK TO SCHOOL 2026National initiatives are pushing review times well below EU-wide targetsThu, 20 Aug 2026 16:23:45 -0700https://www.biocentury.com/article/660310/big-ambitions-big-fractures-europe-s-fih-conundrum-back-to-school-2026https://www.biocentury.com/article/660310/big-ambitions-big-fractures-europe-s-fih-conundrum-back-to-school-2026?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONBIG AMBITIONS, BIG FRACTURES — EUROPE’S FIH CONUNDRUM: BACK TO SCHOOL 2026Can Europe overcome its fractured regulatory environment to be globally competitive?Thu, 20 Aug 2026 15:02:57 -0700https://www.biocentury.com/article/660429/outside-of-china-other-asian-biotech-hubs-have-early-ambitions-toohttps://www.biocentury.com/article/660429/outside-of-china-other-asian-biotech-hubs-have-early-ambitions-too?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONOUTSIDE OF CHINA, OTHER ASIAN BIOTECH HUBS HAVE EARLY AMBITIONS, TOOBack to School 2026: Korea, Taiwan, and Singapore seek earlier roles in global development, while Japan removes barriers to joining global trialsWed, 19 Aug 2026 17:41:07 -0700https://www.biocentury.com/article/660329/australia-looks-beyond-healthy-volunteers-to-defend-phase-i-edge-back-to-school-2026https://www.biocentury.com/article/660329/australia-looks-beyond-healthy-volunteers-to-defend-phase-i-edge-back-to-school-2026?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONAUSTRALIA LOOKS BEYOND HEALTHY VOLUNTEERS TO DEFEND PHASE I EDGE: BACK TO SCHOOL 2026Government and CRO initiatives aim to streamline trial infrastructure and extend early studies into patient cohorts as global competition intensifiesWed, 19 Aug 2026 17:13:12 -0700https://www.biocentury.com/article/660577/moderna-merck-phase-iii-win-opens-door-to-personalized-neoantigen-vaccineshttps://www.biocentury.com/article/660577/moderna-merck-phase-iii-win-opens-door-to-personalized-neoantigen-vaccines?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTMODERNA, MERCK PHASE III WIN OPENS DOOR TO PERSONALIZED NEOANTIGEN VACCINESMelanoma adjuvant success could mark a turnaround for ModernaWed, 19 Aug 2026 17:03:33 -0700https://www.biocentury.com/article/660573/pick-of-trump-loyalist-overton-revives-questions-of-fda-independencehttps://www.biocentury.com/article/660573/pick-of-trump-loyalist-overton-revives-questions-of-fda-independence?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWPICK OF TRUMP LOYALIST OVERTON REVIVES QUESTIONS OF FDA INDEPENDENCE Johns Hopkins-trained physician was chief policy officer at Center for a Healthy America before joining White HouseWed, 19 Aug 2026 08:02:03 -0700https://www.biocentury.com/article/660557/science-spotlight-a-late-acting-antimalarial-turns-infection-into-vaccinationhttps://www.biocentury.com/article/660557/science-spotlight-a-late-acting-antimalarial-turns-infection-into-vaccination?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: A LATE-ACTING ANTIMALARIAL TURNS INFECTION INTO VACCINATION BioCentury’s translational roundup also includes research on hypertension, asthma, and brain-penetrant TEAD inhibitorsTue, 18 Aug 2026 17:12:40 -0700https://www.biocentury.com/article/660388/china-s-value-proposition-in-first-in-human-trials-back-to-school-2026https://www.biocentury.com/article/660388/china-s-value-proposition-in-first-in-human-trials-back-to-school-2026?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONCHINA’S VALUE PROPOSITION IN FIRST-IN-HUMAN TRIALS: BACK TO SCHOOL 2026On the edge of the radar just a few years ago, China has moved center stage in FIH trials by continually innovating and modernizing rulesTue, 18 Aug 2026 16:48:51 -0700https://www.biocentury.com/article/660555/aiming-for-larger-rare-disease-market-biomarin-buys-alesta-programhttps://www.biocentury.com/article/660555/aiming-for-larger-rare-disease-market-biomarin-buys-alesta-program?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSAIMING FOR LARGER RARE DISEASE MARKET, BIOMARIN BUYS ALESTA PROGRAMAcquisition-and-spinout deal brings hypophosphatasia program into BioMarin’s skeletal disease portfolioTue, 18 Aug 2026 15:33:05 -0700https://www.biocentury.com/article/660539/summer-s-venture-wave-drugging-beta-catenin-capricor-fdahttps://www.biocentury.com/article/660539/summer-s-venture-wave-drugging-beta-catenin-capricor-fda?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCESUMMER’S VENTURE WAVE; DRUGGING BETA-CATENIN; CAPRICOR & FDA  Thirteen venture rounds last week brought in nearly $800MMon, 17 Aug 2026 18:23:09 -0700https://www.biocentury.com/article/660359/going-beyond-trialblazer-to-speed-fih-trialshttps://www.biocentury.com/article/660359/going-beyond-trialblazer-to-speed-fih-trials?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONGOING BEYOND TRIALBLAZER TO SPEED FIH TRIALSBack to School 2026: Proposals center on emulating Australia, integrating trials into routine careMon, 17 Aug 2026 16:48:15 -0700https://www.biocentury.com/article/660349/u-s-aims-to-slash-pre-ind-timelines-back-to-school-2026https://www.biocentury.com/article/660349/u-s-aims-to-slash-pre-ind-timelines-back-to-school-2026?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONU.S. AIMS TO SLASH PRE-IND TIMELINES: BACK TO SCHOOL 2026Cutting the time needed to file an IND is low-hanging fruitMon, 17 Aug 2026 16:45:07 -0700https://www.biocentury.com/article/660517/pivotal-misses-punish-eyepoint-and-tenaxhttps://www.biocentury.com/article/660517/pivotal-misses-punish-eyepoint-and-tenax?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTPIVOTAL MISSES PUNISH EYEPOINT AND TENAXBioCentury’s Clinical Report Aug. 10-17Mon, 17 Aug 2026 14:45:11 -0700https://www.biocentury.com/article/660542/slate-redx-to-reach-nasdaq-via-reverse-mergers-deals-reporthttps://www.biocentury.com/article/660542/slate-redx-to-reach-nasdaq-via-reverse-mergers-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSSLATE, REDX TO REACH NASDAQ VIA REVERSE MERGERS: DEALS REPORTPlus: Bankrupt Sangamo’s assets go to Lilly, PTC; and moreMon, 17 Aug 2026 14:36:11 -0700https://www.biocentury.com/article/660495/will-capricor-s-latest-move-give-deramiocel-new-lifehttps://www.biocentury.com/article/660495/will-capricor-s-latest-move-give-deramiocel-new-life?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEWILL CAPRICOR’S LATEST MOVE GIVE DERAMIOCEL NEW LIFE?Spark for shares still leaves stock a long way from Phase III winFri, 14 Aug 2026 19:03:06 -0700https://www.biocentury.com/article/660460/protuoso-bio-building-mix-and-match-multi-functional-biologicshttps://www.biocentury.com/article/660460/protuoso-bio-building-mix-and-match-multi-functional-biologics?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEPROTUOSO BIO: BUILDING MIX-AND-MATCH MULTI-FUNCTIONAL BIOLOGICSThe hub-and-spoke-structured company combines diverse protein modalities into single molecules for synergistic effects in complex diseasesFri, 14 Aug 2026 18:11:14 -0700https://www.biocentury.com/article/660480/boulevard-homing-in-on-b-cell-biology-in-autoimmunityhttps://www.biocentury.com/article/660480/boulevard-homing-in-on-b-cell-biology-in-autoimmunity?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEBOULEVARD: HOMING IN ON B CELL BIOLOGY IN AUTOIMMUNITYDeerfield-incubated Boulevard launched with $65M to develop differentiated B cell-directed therapiesFri, 14 Aug 2026 17:15:34 -0700https://www.biocentury.com/article/660491/syndicate-backs-maplight-illuminating-path-forward-in-schizophrenia-public-equity-reporthttps://www.biocentury.com/article/660491/syndicate-backs-maplight-illuminating-path-forward-in-schizophrenia-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCESYNDICATE BACKS MAPLIGHT, ILLUMINATING PATH FORWARD IN SCHIZOPHRENIA: PUBLIC EQUITY REPORTPlus: Follow-ons for AbCellera and Silence; Vogenx’s IPO; and moreFri, 14 Aug 2026 16:14:43 -0700https://www.biocentury.com/article/660475/khartis-emerges-from-stealth-with-95m-to-challenge-tepezza-venture-reporthttps://www.biocentury.com/article/660475/khartis-emerges-from-stealth-with-95m-to-challenge-tepezza-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEKHARTIS EMERGES FROM STEALTH WITH $95M TO CHALLENGE TEPEZZA: VENTURE REPORTPlus: Rounds for Boulevard, Vaderis, Infinimmune, K2 and moreThu, 13 Aug 2026 18:20:10 -0700https://www.biocentury.com/article/660484/global-drugs-that-made-the-grade-in-china-in-2025https://www.biocentury.com/article/660484/global-drugs-that-made-the-grade-in-china-in-2025?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEGLOBAL DRUGS THAT MADE THE GRADE IN CHINA IN 2025NMPA approved 60 drugs and vaccines already marketed abroad, with Merck leading the sponsorsThu, 13 Aug 2026 18:16:42 -0700https://www.biocentury.com/article/660478/vir-cfo-o-byrne-joining-olemahttps://www.biocentury.com/article/660478/vir-cfo-o-byrne-joining-olema?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSVIR CFO O’BYRNE JOINING OLEMAPlus: Changes at Zenas, Kamada and moreThu, 13 Aug 2026 17:12:01 -0700https://www.biocentury.com/article/660458/science-spotlight-regeneron-s-genomics-derived-metabolic-targethttps://www.biocentury.com/article/660458/science-spotlight-regeneron-s-genomics-derived-metabolic-target?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: REGENERON’S GENOMICS-DERIVED METABOLIC TARGETBioCentury’s translational roundup also features AI-designed bacteriophages and a peptide strategy for immunogenic tumor cell deathWed, 12 Aug 2026 17:27:53 -0700https://www.biocentury.com/article/660442/five-approaches-to-drug-cancer-s-undruggable-catenin-pathwayhttps://www.biocentury.com/article/660442/five-approaches-to-drug-cancer-s-undruggable-catenin-pathway?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTFIVE APPROACHES TO DRUG CANCER’S ‘UNDRUGGABLE’ Β-CATENIN PATHWAYClinical companies are targeting five different nodes to separate oncogenic signaling from Wnt’s roles in healthy tissueWed, 12 Aug 2026 16:53:50 -0700https://www.biocentury.com/article/660452/coregen-one-gene-knockout-many-solid-tumorshttps://www.biocentury.com/article/660452/coregen-one-gene-knockout-many-solid-tumors?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILECOREGEN: ONE GENE KNOCKOUT, MANY SOLID TUMORSHouston-based company is knocking out a master transcriptional regulator in regulatory T cells to strip solid tumors of their immune cloakWed, 12 Aug 2026 16:31:11 -0700https://www.biocentury.com/article/660447/next-chapter-for-legend-s-huang-comes-atop-k2https://www.biocentury.com/article/660447/next-chapter-for-legend-s-huang-comes-atop-k2?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSNEXT CHAPTER FOR LEGEND’S HUANG COMES ATOP K2Plus: C-suite overhaul at Bicara, includes CEO succession plan — and moreTue, 11 Aug 2026 18:30:33 -0700https://www.biocentury.com/article/660412/fda-moving-fast-on-expedited-ind-pilothttps://www.biocentury.com/article/660412/fda-moving-fast-on-expedited-ind-pilot?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWFDA MOVING FAST ON EXPEDITED IND PILOTThird-party reviewers to be selected by year-end, IND submissions to start next yearTue, 11 Aug 2026 16:36:18 -0700https://www.biocentury.com/article/660444/july-fda-approvals-deliver-first-products-for-three-biotechshttps://www.biocentury.com/article/660444/july-fda-approvals-deliver-first-products-for-three-biotechs?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEJULY FDA APPROVALS DELIVER FIRST PRODUCTS FOR THREE BIOTECHSSix novel drugs include first oral PCSK9 inhibitorTue, 11 Aug 2026 15:08:16 -0700https://www.biocentury.com/article/660433/fih-urgency-in-the-u-s-plus-federated-learning-biotech-ipos-a-biocentury-podcasthttps://www.biocentury.com/article/660433/fih-urgency-in-the-u-s-plus-federated-learning-biotech-ipos-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTFIH URGENCY IN THE U.S. PLUS: FEDERATED LEARNING, BIOTECH IPOS — A BIOCENTURY PODCASTPressure is on U.S. stakeholders to respond to challenges from China, Australia, to run first-in-human trials faster and more efficientlyMon, 10 Aug 2026 17:55:18 -0700https://www.biocentury.com/article/660432/jazz-expands-neuro-reach-with-rare-epilepsy-takeout-deals-reporthttps://www.biocentury.com/article/660432/jazz-expands-neuro-reach-with-rare-epilepsy-takeout-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSJAZZ EXPANDS NEURO REACH WITH RARE EPILEPSY TAKEOUT: DEALS REPORTJazz to obtain KCNT1+ epilepsy program via $1.3B acquisition of Actio; plus Tarsus’ $800M takeout of Alkeus for Stargardt candidate; and moreMon, 10 Aug 2026 16:24:19 -0700https://www.biocentury.com/article/660414/auchincloss-bill-would-embed-trials-in-routine-care-speed-fih-startshttps://www.biocentury.com/article/660414/auchincloss-bill-would-embed-trials-in-routine-care-speed-fih-starts?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWAUCHINCLOSS BILL WOULD EMBED TRIALS IN ROUTINE CARE, SPEED FIH STARTSSweeping bipartisan trial reform proposal borrows from Australian fast-track modelMon, 10 Aug 2026 15:58:24 -0700https://www.biocentury.com/article/660435/silence-abcellera-emerge-as-best-in-class-contenders-as-sionna-sinkshttps://www.biocentury.com/article/660435/silence-abcellera-emerge-as-best-in-class-contenders-as-sionna-sinks?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTSILENCE, ABCELLERA EMERGE AS BEST-IN-CLASS CONTENDERS AS SIONNA SINKSBioCentury’s Clinical Report for Aug. 4-10Mon, 10 Aug 2026 15:28:40 -0700https://www.biocentury.com/article/660427/wuxi-apptec-wins-preliminary-injunction-in-1260h-casehttps://www.biocentury.com/article/660427/wuxi-apptec-wins-preliminary-injunction-in-1260h-case?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWWUXI APPTEC WINS PRELIMINARY INJUNCTION IN 1260H CASEJudge rules DoD’s designation of WuXi AppTec as ‘Chinese military company’ was likely arbitrary and capriciousSun, 09 Aug 2026 08:28:33 -0700https://www.biocentury.com/article/660378/mirati-vet-christensen-named-ceo-of-well-funded-start-up-terremotohttps://www.biocentury.com/article/660378/mirati-vet-christensen-named-ceo-of-well-funded-start-up-terremoto?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSMIRATI VET CHRISTENSEN NAMED CEO OF WELL-FUNDED START-UP TERREMOTOPlus: Jennifer Taubert retiring after long career at J&J and moreFri, 07 Aug 2026 17:47:05 -0700https://www.biocentury.com/article/660407/four-biotechs-raise-over-1-2b-in-strong-ipo-run-public-equity-reporthttps://www.biocentury.com/article/660407/four-biotechs-raise-over-1-2b-in-strong-ipo-run-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEFOUR BIOTECHS RAISE OVER $1.2B IN STRONG IPO RUN: PUBLIC EQUITY REPORTTwenty biotechs have raised a combined $6.9B in NASDAQ IPOs this year, with 14 posting first-day gainsFri, 07 Aug 2026 17:14:11 -0700https://www.biocentury.com/article/660424/fda-regulatory-moves-reflect-a-steadying-shiphttps://www.biocentury.com/article/660424/fda-regulatory-moves-reflect-a-steadying-ship?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONFDA REGULATORY MOVES REFLECT A STEADYING SHIPTherapies from Moderna, Replimune emerge from controversy, earning approval alongside Takeda nacrolepsy drug Fri, 07 Aug 2026 16:34:12 -0700https://www.biocentury.com/article/660416/otsuka-s-voyxact-raises-the-bar-in-iga-nephropathyhttps://www.biocentury.com/article/660416/otsuka-s-voyxact-raises-the-bar-in-iga-nephropathy?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEOTSUKA’S VOYXACT RAISES THE BAR IN IGA NEPHROPATHYPhase III eGFR slope data suggest the anti-APRIL mAb may halt or reverse kidney function declineFri, 07 Aug 2026 15:14:17 -0700https://www.biocentury.com/article/660408/biotech-in-the-balance-a-conversation-with-jeremy-levinhttps://www.biocentury.com/article/660408/biotech-in-the-balance-a-conversation-with-jeremy-levin?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWBIOTECH IN THE BALANCE: A CONVERSATION WITH JEREMY LEVINFormer Teva CEO, BIO chair discusses the future of biotechThu, 06 Aug 2026 18:26:37 -0700https://www.biocentury.com/article/660405/lifemine-draws-263m-to-advance-calcineurin-inhibitor-for-transplant-rejection-venture-reporthttps://www.biocentury.com/article/660405/lifemine-draws-263m-to-advance-calcineurin-inhibitor-for-transplant-rejection-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCELIFEMINE DRAWS $263M TO ADVANCE CALCINEURIN INHIBITOR FOR TRANSPLANT REJECTION: VENTURE REPORTPlus Asia-to-West NewCo Expedition Therapeutics raises $115M series BThu, 06 Aug 2026 15:54:40 -0700https://www.biocentury.com/article/660288/coultreon-building-a-cleaner-sik3-inhibitor-for-autoimmune-diseasehttps://www.biocentury.com/article/660288/coultreon-building-a-cleaner-sik3-inhibitor-for-autoimmune-disease?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILECOULTREON: BUILDING A CLEANER SIK3 INHIBITOR FOR AUTOIMMUNE DISEASEBacked by a $125M series A, the Galapagos spinout believes selective SIK3 inhibition can avoid the toxicity that constrained a dual SIK2/3 inhibitorThu, 06 Aug 2026 15:41:41 -0700https://www.biocentury.com/article/660366/science-spotlight-base-editing-to-reduce-toxic-htt-fragmentshttps://www.biocentury.com/article/660366/science-spotlight-base-editing-to-reduce-toxic-htt-fragments?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: BASE EDITING TO REDUCE TOXIC HTT FRAGMENTSBioCentury’s translational roundup also includes a 5-HT2AR agonist for CRC and ‘SECmeres’ for Alzheimer’s liquid biopsyWed, 05 Aug 2026 18:00:15 -0700https://www.biocentury.com/article/660356/turning-cold-adaptation-into-metabolic-medicines-q-a-with-shingo-kajimurahttps://www.biocentury.com/article/660356/turning-cold-adaptation-into-metabolic-medicines-q-a-with-shingo-kajimura?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONTURNING COLD ADAPTATION INTO METABOLIC MEDICINES: Q&A WITH SHINGO KAJIMURAThe Montrone-Seigel Prize winner discusses how activating fat’s calorie-burning machinery could complement appetite-suppressing obesity drugsWed, 05 Aug 2026 17:25:30 -0700https://www.biocentury.com/article/660394/lilly-widens-glp-1-injectable-lead-over-novo-but-lags-on-oral-saleshttps://www.biocentury.com/article/660394/lilly-widens-glp-1-injectable-lead-over-novo-but-lags-on-oral-sales?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTELILLY WIDENS GLP-1 INJECTABLE LEAD OVER NOVO BUT LAGS ON ORAL SALESLilly’s Mounjaro continues lead as top-selling GLP-1R agonist injectable, but debut quarter sales for Foundayo behind oral WegovyWed, 05 Aug 2026 16:29:17 -0700https://www.biocentury.com/article/660391/former-temasek-exec-alsagoff-joins-flagshiphttps://www.biocentury.com/article/660391/former-temasek-exec-alsagoff-joins-flagship?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSFORMER TEMASEK EXEC ALSAGOFF JOINS FLAGSHIP Sobi CEO Oelkers to lead BioNTech and more in BioCentury’s latest management columnTue, 04 Aug 2026 18:18:25 -0700https://www.biocentury.com/article/660368/calissa-photodynamic-therapy-for-durable-clearance-of-port-wine-stainshttps://www.biocentury.com/article/660368/calissa-photodynamic-therapy-for-durable-clearance-of-port-wine-stains?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILECALISSA: PHOTODYNAMIC THERAPY FOR DURABLE CLEARANCE OF PORT-WINE STAINSNew York-based dermatology company running a Phase II trial of a drug-device combo already used in ChinaTue, 04 Aug 2026 17:11:36 -0700https://www.biocentury.com/article/660354/fixing-your-own-house-first-academic-centers-on-fih-trialshttps://www.biocentury.com/article/660354/fixing-your-own-house-first-academic-centers-on-fih-trials?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTFIXING YOUR OWN HOUSE FIRST: ACADEMIC CENTERS ON FIH TRIALSAcademic medical centers own many of the decisions that could speed the timelines for starting first-in-human clinical trialsTue, 04 Aug 2026 16:34:43 -0700